{"product_id":"when-a-parathyroid-tumor-returns-after-11-years-the-diagnostic-challenge-between-atypical-adenoma-and-carcinoma","title":"When a Parathyroid Tumor Returns After 11 Years: The Diagnostic Challenge Between Atypical Adenoma and Carcinoma","description":"\u003cp\u003eThis case report follows a woman who was diagnosed with primary hyperparathyroidism at age 32, underwent surgery for what was classified as an atypical parathyroid adenoma, and then experienced a tumor recurrence 11 years later—raising serious questions about whether the original diagnosis was correct or whether she actually had a rare parathyroid carcinoma. After a second surgery in 2007 and 26 years of follow-up, the tumor was ultimately reclassified as a recurrence of the atypical adenoma, though even that conclusion was reached with difficulty. The case highlights how challenging it is for doctors to distinguish between atypical parathyroid adenomas and parathyroid carcinomas, and why lifelong monitoring after parathyroid surgery is so important.\u003c\/p\u003e\n\n\u003ch1\u003eWhen a Parathyroid Tumor Returns After 11 Years: The Diagnostic Challenge Between Atypical Adenoma and Carcinoma\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Understanding Primary Hyperparathyroidism\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#case-1996\"\u003eThe Patient's Story: Initial Diagnosis in 1996\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recurrence-2007\"\u003eThe Tumor Returns: 2007\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#second-surgery\"\u003eThe Second Surgery: July 2007\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#pathology\"\u003eWhat the Pathologist Found\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recovery\"\u003eRecovery and Long-Term Follow-Up\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#discussion\"\u003eWhy Parathyroid Tumors Are So Difficult to Diagnose\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations of This Case Report\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eParathyroid tumors can recur many years after surgery, even 11 years later, so lifelong follow-up is essential.\u003c\/li\u003e\n\u003cli\u003eDistinguishing atypical parathyroid adenoma from carcinoma is difficult; vascular invasion and distant metastases are key signs of cancer.\u003c\/li\u003e\n\u003cli\u003eCapsular rupture during parathyroid surgery may facilitate tumor recurrence through cell seeding or incomplete removal.\u003c\/li\u003e\n\u003cli\u003eThe overall recurrence rate of atypical parathyroid adenomas is about 3% after surgical removal.\u003c\/li\u003e\n\u003cli\u003eLong-term vitamin D supplementation and regular blood tests for calcium and PTH help detect recurrence and maintain health.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Understanding Primary Hyperparathyroidism\u003c\/h2\u003e\n\n\u003cp\u003ePrimary hyperparathyroidism is a condition in which one or more of the four parathyroid glands—tiny glands located in the neck behind the thyroid—produce too much \u003cstrong\u003eparathyroid hormone (PTH)\u003c\/strong\u003e. This hormone normally regulates calcium levels in the blood, so when too much of it is produced, calcium levels rise, a condition called \u003cstrong\u003ehypercalcemia\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eWhile primary hyperparathyroidism is the most common cause of hypercalcemia, the condition itself is relatively uncommon, affecting \u003cstrong\u003eless than 1%\u003c\/strong\u003e of the general population.\u003c\/p\u003e\n\n\u003cp\u003eThe causes of primary hyperparathyroidism break down as follows:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eParathyroid adenomas or atypical adenomas\u003c\/strong\u003e (benign tumors): 85% of cases\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eParathyroid hyperplasia\u003c\/strong\u003e (enlargement of all four glands): 10% of cases\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple adenomas\u003c\/strong\u003e: 4% of cases\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eParathyroid carcinoma\u003c\/strong\u003e (cancer): less than 1% of cases\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eParathyroid carcinoma is exceptionally rare, but it is a serious and often fatal cause of primary hyperparathyroidism. To date, there is still no clear-cut diagnostic pathway established for parathyroid carcinoma, which results in significant diagnostic ambiguity and complexity. Clinical differentiation between a benign parathyroid adenoma and a carcinoma is extremely challenging, and ultimately the diagnosis remains a \u003cstrong\u003ehistopathological\u003c\/strong\u003e one—meaning it requires examining the tissue under a microscope after surgery.\u003c\/p\u003e\n\n\u003ch2 id=\"case-1996\"\u003eThe Patient's Story: Initial Diagnosis in 1996\u003c\/h2\u003e\n\n\u003cp\u003eIn 1996, a 32-year-old, otherwise healthy woman was diagnosed with primary hyperparathyroidism during a routine health check. Her \u003cstrong\u003eparathyroid hormone (PTH)\u003c\/strong\u003e serum levels were elevated to \u003cstrong\u003e127 ng\/L\u003c\/strong\u003e (normal range: 10–65 ng\/L), and her calcium serum levels were elevated up to \u003cstrong\u003e3.6 mmol\/L\u003c\/strong\u003e (normal range: 2–2.5 mmol\/L). Other laboratory investigations from 1996 that led to the diagnosis are no longer accessible.\u003c\/p\u003e\n\n\u003cp\u003eInterestingly, at the time of diagnosis, the patient did not exhibit any specific symptoms attributable to hypercalcemia. This is not unusual—many patients with hypercalcemia have subtle or no symptoms at all, which is one reason the condition can go undetected for years.\u003c\/p\u003e\n\n\u003cp\u003eA neck ultrasound scan revealed a \u003cstrong\u003ecaudal (lower) parathyroid tumor on the left side\u003c\/strong\u003e. On \u003cstrong\u003eJune 3, 1996\u003c\/strong\u003e, surgeons performed a subtotal left-sided thyroid lobectomy (removal of part of the left thyroid lobe) and a caudal parathyroidectomy (removal of the lower parathyroid gland) to surgically remove the presumed benign parathyroid adenoma.\u003c\/p\u003e\n\n\u003cp\u003eDuring the operation, however, an important complication occurred: \u003cstrong\u003ethe capsule of the tumor ruptured\u003c\/strong\u003e. This detail would later become highly significant in understanding the patient's disease course.\u003c\/p\u003e\n\n\u003cp\u003eAfter the operation, the patient's calcium levels returned to normal, and PTH levels were reported in the medical record to be within the normal range, though the exact PTH serum levels after the 1996 operation are no longer available.\u003c\/p\u003e\n\n\u003cp\u003eThe histological report from 1996 showed an \u003cstrong\u003eatypical, predominately oncocytic parathyroid adenoma\u003c\/strong\u003e (oncocytic refers to tumor cells packed with mitochondria, giving them a distinctive appearance under the microscope). No secure signs matching the criteria of parathyroid malignancy—such as vascular invasion (cancer cells entering blood vessels) or breaches through the capsule with invasion of surrounding soft tissue—were found.\u003c\/p\u003e\n\n\u003cp\u003eHowever, some signs that can favor parathyroid carcinoma were present, including:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eRelatively high mitotic figures (cells dividing more rapidly than normal)\u003c\/li\u003e\n  \u003cli\u003eA distinct nuclear morphology with prominent nucleoli (enlarged structures inside the cell nucleus)\u003c\/li\u003e\n  \u003cli\u003eFibrous septa (bands of scar-like tissue) emerging from a thick fibrous capsule\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eUnfortunately, the original histopathological material from 1996 is no longer available, but this specific information is recorded in the pathology report.\u003c\/p\u003e\n\n\u003cp\u003eDespite the ambiguous pathological findings, the tumor was classified at that time as an \u003cstrong\u003eatypical parathyroid adenoma\u003c\/strong\u003e, and regular follow-up of local findings, blood calcium, and PTH levels was recommended.\u003c\/p\u003e\n\n\u003ch2 id=\"recurrence-2007\"\u003eThe Tumor Returns: 2007\u003c\/h2\u003e\n\n\u003cp\u003eDuring a routine follow-up appointment in \u003cstrong\u003e2007—11 years after the first presentation\u003c\/strong\u003e—elevated levels of intact PTH of \u003cstrong\u003e703 ng\/L\u003c\/strong\u003e were found. A control test 2 weeks later still showed elevated levels of \u003cstrong\u003e218 ng\/L\u003c\/strong\u003e. This difference in PTH values was initially explained by the fact that PTH is secreted in a \u003cstrong\u003epulsatile manner\u003c\/strong\u003e, meaning levels naturally fluctuate.\u003c\/p\u003e\n\n\u003cp\u003eAt that time, the patient's calcium levels were in the upper normal range at \u003cstrong\u003e2.48 mmol\/L\u003c\/strong\u003e (normal range: 2–2.5 mmol\/L). Three weeks later, another laboratory control showed elevated levels of intact PTH of \u003cstrong\u003e104.6 ng\/L\u003c\/strong\u003e and elevated calcium levels of \u003cstrong\u003e2.59 mmol\/L\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eAdditionally, the patient's \u003cstrong\u003e25-OH vitamin D3 level\u003c\/strong\u003e was low at \u003cstrong\u003e7.1 ng\/mL\u003c\/strong\u003e (normal range: 20–50 ng\/mL), which was explained as a result of decreased dietary intake and reduced sun exposure, since the patient lacked clinical symptoms.\u003c\/p\u003e\n\n\u003cp\u003eThe laboratory results from June 26, 2007, when the recurrence was diagnosed, are summarized below:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eIntact PTH: \u003cstrong\u003e104.6 ng\/L\u003c\/strong\u003e (normal: 10–65 ng\/L)\u003c\/li\u003e\n  \u003cli\u003ePTH-related peptide: \u003cstrong\u003e\u0026lt;1.5 pmol\/L\u003c\/strong\u003e (normal: \u0026lt;1.5 pmol\/L)\u003c\/li\u003e\n  \u003cli\u003eTotal serum calcium: \u003cstrong\u003e2.59 mmol\/L\u003c\/strong\u003e (normal: 2–2.5 mmol\/L)\u003c\/li\u003e\n  \u003cli\u003eIonized serum calcium: \u003cstrong\u003e1.36 mmol\/L\u003c\/strong\u003e (normal: 1.17–1.29 mmol\/L)\u003c\/li\u003e\n  \u003cli\u003eUrinary calcium: \u003cstrong\u003e8.1 mmol\/24h\u003c\/strong\u003e (normal: \u0026lt;6.20 mmol\/24h)\u003c\/li\u003e\n  \u003cli\u003eSerum phosphate: \u003cstrong\u003e0.64 mmol\/L\u003c\/strong\u003e (normal: 0.84–1.45 mmol\/L)\u003c\/li\u003e\n  \u003cli\u003e25-OH vitamin D3: \u003cstrong\u003e7.1 ng\/mL\u003c\/strong\u003e (normal: 20–50 ng\/mL)\u003c\/li\u003e\n  \u003cli\u003eAlkaline phosphatase: \u003cstrong\u003e113 U\/L\u003c\/strong\u003e (normal: 40–140 U\/L)\u003c\/li\u003e\n  \u003cli\u003eBone alkaline phosphatase: \u003cstrong\u003e8.9 μg\/L\u003c\/strong\u003e (normal: 4.9–22.7 μg\/L)\u003c\/li\u003e\n  \u003cli\u003eOsteocalcin: \u003cstrong\u003e18.0 μg\/L\u003c\/strong\u003e (normal: 15–46 μg\/L)\u003c\/li\u003e\n  \u003cli\u003eN-telopeptide: \u003cstrong\u003e5.9 nmol\/L\u003c\/strong\u003e (normal: 6.2–19 nmol\/L)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eA \u003cstrong\u003emagnetic resonance imaging (MRI) scan\u003c\/strong\u003e of the neck was performed and showed a \u003cstrong\u003e5 mm left-sided paratracheal soft tissue tumor\u003c\/strong\u003e (a small growth located next to the windpipe on the left side). At that point, the suspicion arose that the initial tumor classified as an atypical adenoma might have been \u003cstrong\u003emisdiagnosed\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eBecause the initial tumor showed features suspicious of parathyroid carcinoma, and the patient now presented with a tumor recurrence, doctors suspected she might have a \u003cstrong\u003eparathyroid carcinoma recurrence\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eA \u003cstrong\u003eTc-99m sestamibi scintigraphy\u003c\/strong\u003e (a nuclear medicine scan that helps locate parathyroid tissue) was performed and showed a well-defined left-sided activity enhancement corresponding to the tumor detected on the MRI. Notably, no evidence of distant metastases or suspicious lymph nodes was found.\u003c\/p\u003e\n\n\u003cp\u003eSubsequently, a neck sonography (ultrasound) was performed, showing an \u003cstrong\u003einhomogeneous hypoechoic polycystic defined area measuring 17 × 10 mm\u003c\/strong\u003e—meaning the tumor appeared as an irregular, fluid-filled area that was clearly outside the thyroid gland and distinctly located below the small remaining portion of the left thyroid lobe.\u003c\/p\u003e\n\n\u003ch2 id=\"second-surgery\"\u003eThe Second Surgery: July 2007\u003c\/h2\u003e\n\n\u003cp\u003eThe patient was referred to an endocrine surgical center in Halle, Germany, for the ensuing operation. On \u003cstrong\u003eJuly 6, 2007\u003c\/strong\u003e, at the age of 43, she received an \u003cstrong\u003een-bloc resection\u003c\/strong\u003e (removal of the tumor as a whole, along with surrounding tissue) of the tumor recurrence, which measured \u003cstrong\u003e12 mm\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThe tumor was in very close proximity to the \u003cstrong\u003eleft recurrent laryngeal nerve\u003c\/strong\u003e—the nerve that controls the vocal cords on the left side—but the nerve's function could be preserved during the operation. The intra-operative photographic documentation clearly demonstrated that the surgical team assumed this was a parathyroid carcinoma recurrence at that point.\u003c\/p\u003e\n\n\u003cp\u003eThe patient's \u003cstrong\u003eintraoperative PTH\u003c\/strong\u003e was initially \u003cstrong\u003e113 ng\/L\u003c\/strong\u003e and normalized to \u003cstrong\u003e11.1 ng\/L\u003c\/strong\u003e after the tumor was resected—a strong indicator that all hyperfunctioning parathyroid tissue had been successfully removed.\u003c\/p\u003e\n\n\u003ch2 id=\"pathology\"\u003eWhat the Pathologist Found\u003c\/h2\u003e\n\n\u003cp\u003eThe pathological findings from the second surgery suggested parathyroid carcinoma, including several concerning features:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTrabecular and diffuse growth patterns\u003c\/strong\u003e distinctly different from normal parathyroid tissue\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTumor cell pleomorphism\u003c\/strong\u003e (cells of varying shapes and sizes) with macronucleoli (enlarged nucleoli)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMitotic figures\u003c\/strong\u003e: up to 3 mitoses per one high-power field, and 52 mitoses per 50 high-power fields\u003c\/li\u003e\n  \u003cli\u003eA \u003cstrong\u003eproliferation index (Ki-67)\u003c\/strong\u003e of up to 10%, indicating relatively rapid cell division\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTumor necrosis\u003c\/strong\u003e (areas of dead tissue within the tumor)\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eTumor infiltration into surrounding soft tissue and striated muscle\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eUnder the microscope, the pathologist observed desmoplastic stroma reaction (dense scar-like tissue induced by the tumor), invasion of soft tissue and skeletal muscle, dysplastic (abnormal) tumor cells adjacent to normal parathyroid tissue, and cord-like infiltrating tumor cells. Immunohistochemistry for \u003cstrong\u003eparafibromin\u003c\/strong\u003e—a protein that is often lost in parathyroid carcinoma—was negative in tumor cells but positive in normal parathyroid tissue.\u003c\/p\u003e\n\n\u003cp\u003eThe tumor met certain \u003cstrong\u003eWorld Health Organization (WHO) criteria for malignancy\u003c\/strong\u003e because of three features:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003eMacronucleoli (enlarged nucleoli within the cell nucleus)\u003c\/li\u003e\n  \u003cli\u003eMore than five mitoses per 50 high-power fields (the tumor had 52)\u003c\/li\u003e\n  \u003cli\u003eTumor necrosis (dead tissue within the tumor)\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eHowever, no clear-cut diagnosis of carcinoma could be made due to the \u003cstrong\u003elack of decisive criteria\u003c\/strong\u003e—specifically, \u003cstrong\u003evascular invasion\u003c\/strong\u003e (tumor cells invading blood vessels) was not found, neither by conventional staining methods like hematoxylin and eosin (H\u0026amp;E) and Elastica van Gieson (EvG) staining, nor by immunohistochemistry (CD31, a marker for blood vessel lining cells).\u003c\/p\u003e\n\n\u003cp\u003eThe resection borders (edges of the removed tissue) and the lymph nodes were \u003cstrong\u003efree from tumor\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch2 id=\"recovery\"\u003eRecovery and Long-Term Follow-Up\u003c\/h2\u003e\n\n\u003cp\u003eAfter the second surgery, the patient's calcium levels normalized. However, she developed mild symptoms such as \u003cstrong\u003eirritability, muscle cramps, and fatigue\u003c\/strong\u003e, which were attributed to symptoms of \u003cstrong\u003ehypocalcemia\u003c\/strong\u003e (temporarily low calcium levels after removal of the overactive parathyroid tissue). Oral calcium supplementation was started and discontinued after several weeks.\u003c\/p\u003e\n\n\u003cp\u003eDuring all follow-up appointments over the subsequent years—the last one being held in \u003cstrong\u003eSeptember 2022\u003c\/strong\u003e when the patient was \u003cstrong\u003e58 years old\u003c\/strong\u003e—the patient was feeling well, and both PTH and serum calcium levels remained in normal ranges \u003cstrong\u003ewithout any oral calcium supplementation\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eOne ongoing issue was the patient's vitamin D status. Her 25-hydroxy vitamin D levels were low on follow-up at \u003cstrong\u003e14.6 ng\/mL\u003c\/strong\u003e (normal range: 20–50 ng\/mL). To date, the patient receives \u003cstrong\u003e1,000 units of 25-hydroxy vitamin D orally once a day\u003c\/strong\u003e to ensure an optimal vitamin D3 status.\u003c\/p\u003e\n\n\u003cp\u003eThe patient's vitamin D3 levels were tracked over many years:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e26.06.07: \u003cstrong\u003e7.1 ng\/mL\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e15.03.12: \u003cstrong\u003e14.6 ng\/mL\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e15.12.15: \u003cstrong\u003e7.25 ng\/mL\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e19.02.16: \u003cstrong\u003e44 ng\/mL\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e19.05.16: \u003cstrong\u003e24.6 ng\/mL\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e24.11.16: \u003cstrong\u003e41 ng\/mL\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e18.05.17: \u003cstrong\u003e41.9 ng\/mL\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e17.06.21: \u003cstrong\u003e35.3 ng\/mL\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e09.12.21: \u003cstrong\u003e42.7 ng\/mL\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e29.09.22: \u003cstrong\u003e29.8 ng\/mL\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eRetrospectively, this patient was classified to have a \u003cstrong\u003erecurrence of the atypical parathyroid adenoma\u003c\/strong\u003e, because only some, but not all, histopathological findings were indicative of parathyroid carcinoma. During the 15 years of follow-up after the second operation, no further tumor has recurred to date.\u003c\/p\u003e\n\n\u003ch2 id=\"discussion\"\u003eWhy Parathyroid Tumors Are So Difficult to Diagnose\u003c\/h2\u003e\n\n\u003cp\u003eThis case highlights the formidable difficulties in diagnosing parathyroid carcinoma. The tumor removed during the second operation in 2007 was initially classified as a parathyroid carcinoma, but was later reclassified as an atypical parathyroid adenoma recurrence because of the \u003cstrong\u003elack of distant metastases and vascular invasion\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eParathyroid carcinoma is often diagnosed retrospectively—only after a recurrence of hypercalcemia or hyperparathyroidism occurs, either due to local tumor spread or distant metastases. This is a recurring theme in the medical literature, with several reported cases of parathyroid carcinoma that were originally diagnosed as benign parathyroid adenomas.\u003c\/p\u003e\n\n\u003cp\u003eBiochemical markers can provide clues. Leading biochemical markers suggestive of parathyroid carcinoma include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCalcium levels \u0026gt;3 mmol\/L\u003c\/strong\u003e (normal range: 2–2.5 mmol\/L)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePTH elevations greater than 2–3 times the normal range\u003c\/strong\u003e (normal range: 10–65 ng\/L)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIn clinical practice, calcium levels of \u003cstrong\u003e\u0026gt;4 mmol\/L\u003c\/strong\u003e and PTH levels of \u003cstrong\u003e\u0026gt;1,000 ng\/L\u003c\/strong\u003e are often seen in patients with parathyroid carcinoma. In this patient, the PTH was found to be in the range of \u003cstrong\u003e703 ng\/L\u003c\/strong\u003e only once on follow-up, with a drop to 218 ng\/L just 2 weeks later. This drop could be explained both by the pulsatile (fluctuating) secretion of PTH and by vitamin D deficiency, since the patient's 25-OH vitamin D3 level was 7.1 ng\/mL at that time. Other factors that might affect PTH levels—dehydration, chronic kidney injury, or bisphosphonate intake—were not documented in the medical record. Regardless of this variation, the repeated laboratory findings in this patient were considered too low to be strongly indicative of parathyroid carcinoma.\u003c\/p\u003e\n\n\u003cp\u003eOther conditions must also be considered in the differential diagnosis. \u003cstrong\u003eParathyromatosis\u003c\/strong\u003e is a rare cause of recurrent hyperparathyroidism in which several nodules of hyperfunctioning parathyroid tissue form in the neck or mediastinum (the space between the lungs). Usually, parathyromatosis presents as small, numerous nodules with no real fibrous capsule, unlike parathyroid adenoma or carcinoma. In this patient, the mitotic activity, histomorphological growth pattern, tumor necrosis, presence of a solitary nodule, and the fibrous capsule ruled out parathyromatosis. Additionally, parathyromatosis does not typically infiltrate the surrounding soft tissues and striated muscle as was shown in this patient's tumor. \u003cstrong\u003eFour-gland hyperplasia\u003c\/strong\u003e was also ruled out by neck imaging.\u003c\/p\u003e\n\n\u003cp\u003eNo clear-cut diagnostic workup has been established so far for parathyroid carcinoma. The \u003cstrong\u003eAmerican Joint Committee of Cancer (AJCC)\u003c\/strong\u003e proposed a classification system for parathyroid cancer using the TNM classification of malignant tumors (T = tumor size\/extent, N = lymph node involvement, M = metastasis). However, there is limited data on tumor characteristics and associated prognosis, so no prognostic stages can be concluded from this staging system as yet.\u003c\/p\u003e\n\n\u003cp\u003eAfter surgical excision, certain distinct histological findings can aid the diagnosis of malignancy:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eMitotic figures\u003c\/li\u003e\n  \u003cli\u003eTrabeculated parenchyma (a distinctive ribbon-like growth pattern) including thick fibrous bands\u003c\/li\u003e\n  \u003cli\u003eCapsular or vascular invasion\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eMost importantly, \u003cstrong\u003evascular invasion should lead to a strong suspicion of malignancy\u003c\/strong\u003e. Additionally, in contrast to benign parathyroid tissue seeding (as seen in parathyromatosis), real lymph node or distant metastases are the biological evidence of malignancy. In this case, neither the presence of abnormal mitosis nor the thick fibrous bands initially led to critical clinical judgment and suspicion of malignancy after the first operation in 1996—even though it is doubtful whether the disease course in this particular patient would have changed significantly even if malignancy had been suspected then.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eRecurrence of a parathyroid tumor should always be evaluated critically. \u003cstrong\u003eParathyroid carcinoma has a high tendency of recurrence after surgical excision, affecting 25%–80% of patients.\u003c\/strong\u003e The mean time to recurrence is \u003cstrong\u003e3 years\u003c\/strong\u003e, but it can range from \u003cstrong\u003e1 to 20 years\u003c\/strong\u003e after the initial surgery. A cure is unlikely once a malignant tumor has recurred, but prolonged survival is common.\u003c\/p\u003e\n\n\u003cp\u003eBenign hyperparathyroidism is generally not considered a precancerous condition for the development of parathyroid carcinoma. In contrast, \u003cstrong\u003eatypical parathyroid adenomas are classified to have an uncertain malignant potential\u003c\/strong\u003e—they exhibit some features of parathyroid carcinoma but lack unequivocal features like invasive growth.\u003c\/p\u003e\n\n\u003cp\u003eThe single most effective therapy for parathyroid carcinoma is \u003cstrong\u003ecomplete surgical resection\u003c\/strong\u003e. An \u003cstrong\u003een-bloc resection\u003c\/strong\u003e (removing the tumor whole, along with its capsule and surrounding tissue) should be performed at the time of the first presentation, as this reduces the rate of capsule injury and cell seeding concurrently. In clinical practice, however, only about \u003cstrong\u003e12% of parathyroid carcinoma cases\u003c\/strong\u003e are en-bloc excised at first presentation—meaning most patients do not receive this optimal initial surgery.\u003c\/p\u003e\n\n\u003cp\u003eThis case is particularly instructive because the \u003cstrong\u003ecapsule of the first tumor ruptured during surgery in 1996\u003c\/strong\u003e. The authors note that it is most likely that the tumor recurrence was facilitated by this capsular rupture, either through cell seeding (tumor cells spilling into the surrounding tissue) or incomplete removal of the tumor after the rupture.\u003c\/p\u003e\n\n\u003cp\u003eThe overall recurrence rate of atypical parathyroid adenomas after surgical removal is \u003cstrong\u003e3%\u003c\/strong\u003e, according to the research literature. However, no studies have been conducted on the recurrence rate of atypical parathyroid adenomas after capsular rupture during surgery, so no definitive conclusion can be drawn about the exact effect of capsular rupture on tumor recurrence.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations of This Case Report\u003c\/h2\u003e\n\n\u003cp\u003eAs with any case report, this article describes a single patient's experience, which limits how broadly the findings can be generalized. Several specific limitations are also worth noting:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eThe \u003cstrong\u003ehistopathological material from 1996 is no longer available\u003c\/strong\u003e, so the original tumor could not be re-examined with modern techniques\u003c\/li\u003e\n  \u003cli\u003eThe exact \u003cstrong\u003ePTH serum levels after the 1996 operation are no longer accessible\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eOther laboratory investigations from 1996 that led to the diagnosis of primary hyperparathyroidism are also unavailable\u003c\/li\u003e\n  \u003cli\u003eThe final classification of the tumor as an atypical parathyroid adenoma recurrence rather than parathyroid carcinoma was made \u003cstrong\u003eretrospectively\u003c\/strong\u003e, based on the absence of distant metastasis and vascular invasion\u003c\/li\u003e\n  \u003cli\u003eThere are \u003cstrong\u003eno established guidelines for follow-up regimes\u003c\/strong\u003e for atypical parathyroid adenomas, meaning the follow-up schedule used in this case was determined by clinical judgment rather than evidence-based protocol\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\n\u003cp\u003eBased on this case and the broader medical literature, patients with parathyroid tumors—particularly atypical adenomas—should be aware of the following recommendations:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUndergo lifelong follow-up.\u003c\/strong\u003e Life-long monitoring after parathyroid surgery is essential, since the development of metastases has been documented up to 20 years after initial diagnosis.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMonitor PTH and calcium levels regularly.\u003c\/strong\u003e In this case, the first follow-up after the second surgery occurred every 6 months, and after several years without recurrence, the interval was prolonged to 1 year. Regular blood tests for PTH, calcium, and vitamin D levels can detect recurrence early.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePay attention to vitamin D status.\u003c\/strong\u003e This patient required ongoing vitamin D supplementation (1,000 units daily). Low vitamin D levels can affect PTH measurements and bone health.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSeek specialized surgical expertise.\u003c\/strong\u003e If surgery is needed, an experienced endocrine surgeon should perform an en-bloc resection to minimize the risk of capsule rupture and cell seeding.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBe aware that symptoms can be silent.\u003c\/strong\u003e Hypercalcemia often causes no symptoms, which is why routine follow-up blood tests are critical even when you feel well.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnderstand that diagnosis can evolve.\u003c\/strong\u003e As this case demonstrates, the distinction between atypical parathyroid adenoma and parathyroid carcinoma can be extremely difficult, and classifications may change as more information becomes available.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eIn the future, additional molecular markers might enable a more distinct diagnosis between these conditions. For now, the authors emphasize that a greater level of suspicion of malignancy is required to optimize patient care and achieve a favorable long-term outcome. This case should raise awareness for the differential diagnosis of hypercalcemia and primary hyperparathyroidism, including parathyroid carcinoma and atypical adenoma, and highlight the diagnostic challenges.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is an atypical parathyroid adenoma?\u003c\/h3\u003e\n\u003cp\u003eAn atypical parathyroid adenoma is a benign tumor with some features seen in cancer, such as rapid cell division or fibrous bands, but it lacks clear signs of malignancy like invasion into blood vessels. It is considered to have uncertain cancer potential. Diagnosis is made by examining the tumor tissue under a microscope after surgery.\u003c\/p\u003e\n\u003ch3\u003eWhy did the parathyroid tumor come back 11 years later?\u003c\/h3\u003e\n\u003cp\u003eThe first surgery in 1996 caused the tumor capsule to rupture. The authors believe the recurrence was most likely facilitated by this rupture, either from tumor cells spilling into surrounding tissue or from incomplete removal after the rupture. Not all suspicious features of cancer were present, so it was later classified as a recurrence of the atypical adenoma.\u003c\/p\u003e\n\u003ch3\u003eHow can doctors tell an atypical adenoma from parathyroid carcinoma?\u003c\/h3\u003e\n\u003cp\u003eIt is very difficult. A cancer diagnosis requires clear evidence such as vascular invasion or distant metastases. Features like mitotic figures, tumor necrosis, and invasion into soft tissue suggest cancer, but they are not always conclusive. In this case, the tumor was reclassified as an atypical adenoma because no vascular invasion or distant spread was found.\u003c\/p\u003e\n\u003ch3\u003eWhy is lifelong follow-up needed after parathyroid surgery?\u003c\/h3\u003e\n\u003cp\u003eTumor recurrence can occur many years later, sometimes up to 20 years after initial diagnosis. Regular blood tests for calcium, PTH, and vitamin D can detect recurrence early. In this patient, the tumor returned after 11 years. Even if you feel well, follow-up is essential.\u003c\/p\u003e\n\u003ch3\u003eWhat is the risk of recurrence after removal of an atypical parathyroid adenoma?\u003c\/h3\u003e\n\u003cp\u003eThe overall recurrence rate of atypical parathyroid adenomas after surgical removal is about 3%, according to research. However, no studies have looked specifically at recurrence after capsular rupture during surgery, so the exact effect of rupture on recurrence is not known. Lifelong monitoring is still recommended.\u003c\/p\u003e\n\u003ch3\u003eWhat symptoms did the patient have after surgery, and were they serious?\u003c\/h3\u003e\n\u003cp\u003eAfter the second surgery, the patient developed mild symptoms such as irritability, muscle cramps, and fatigue. These were attributed to temporarily low calcium levels, called hypocalcemia. Oral calcium supplementation was started and stopped after several weeks. No serious complications occurred.\u003c\/p\u003e\n\u003ch3\u003eIf my parathyroid tumor is called an atypical adenoma, should I get a second opinion to check for parathyroid carcinoma after a recurrence?\u003c\/h3\u003e\n\u003cp\u003eParathyroid carcinoma is exceptionally rare and may be misdiagnosed as an atypical adenoma; recurrence can occur up to 20 years later. In one case, a tumor initially classified as atypical adenoma was reclassified only after an 11-year recurrence, because the microscopic features were ambiguous and vascular invasion was absent. Because the diagnosis is histopathological and can evolve, a second opinion that includes review of pathology slides, imaging, and PTH\/calcium trends may help determine whether en-bloc resection is needed. Lifelong monitoring of PTH and calcium levels is essential. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Late recurrence of a single gland primary hyperparathyroidism\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Jessica Kotliarevskaia, Udo Siebolts, Henning Dralle, Frank Schuppert\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication:\u003c\/strong\u003e Clinical Case Reports, 2024, Volume 12, Article e8440. Published by John Wiley \u0026amp; Sons Ltd. Received October 26, 2023; revised December 20, 2023; accepted December 21, 2023. DOI: 10.1002\/ccr3.8440\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAffiliations:\u003c\/strong\u003e Department of Gastroenterology, Endocrinology, Diabetology and General Medicine, Klinikum Kassel, Kassel, Germany; Department of Gastroenterology and Oncology, Vivantes Klinikum Spandau, Berlin, Germany; Institute of Pathology, Martin Luther University, Halle, Germany; Institute of Pathology Cologne University, Cologne, Germany; Department of Surgery, Martin Luther University, Halle, Germany; Department of Endocrine Surgery, University Hospital Essen, Essen, Germany.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFunding:\u003c\/strong\u003e No public or commercial funding was received for this case report. The authors declared no conflicts of interest.\u003c\/p\u003e\n\n\u003cp\u003eThis patient-friendly article is based on peer-reviewed research. Written informed consent was obtained from the patient to publish the original report in accordance with the journal's patient consent policy.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47527617036444,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/products\/when-a-parathyroid-tumor-returns-after-11-years-the-diagnostic-challenge-between-atypical-adenoma-and-carcinoma","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}